Dementia, a progressive disorder that impacts memory and independence, affects millions globally. While many are aware of ...

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...

Researchers at the University of Kentucky (UK) are part of a groundbreaking clinical trial exploring the use of medical ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according ...

Expanded clinical practice guidelines aim to empower all clinicians, regardless of specialty or practice setting to evaluate ...

The doctor said his pulse rate is low, and the medications have a tendency to lower the pulse even more, which can be dangerous. His Alzheimer's stage is 4-5, and his MMSE score was 5 out of 30. Is ...

Digital mental health platforms were supposed to expand access for the neediest patients. Researchers say that hasn’t ...

Delray Medical Center cut the ribbon on its newest high-tech machine last week that targets brain areas to treat movement ...

A report questions the FDA's accelerated approval process citing Sarepta and Biogen therapies as examples. Read more here.

Approvals for drugs from Biogen Inc. and Sarepta Therapeutics Inc. show flaws in the process US drug regulators use to speed ...

Spear Bio Inc., a biotechnology company pioneering next-generation ultra-sensitive immunoassays, today announced that its pTau 217 blood test has been granted Breakthrough Device Designation by the U.